Canada’s Biovail plans to buy Valeant Pharmaceuticals to strengthen US position in specialty CNS, dermatology and generics markets.
Egypt-based Minapharm has acquired 95 per cent of CMO ProBioGen for a possible total of €30.4m ($37.6m).
Know your Lilly from your Lonza? Then test your industry knowledge against colleagues, peers and our community of readers by participating in our exclusive map-based quiz.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
Irish pharmaceutical company Elan says most potential investors are positive about proposal to spin-off drug delivery unit.
Adcock Ingram recorded an 11 per cent rise in profit in the first half of 2010 and is looking to continue this upwards trend through manufacturing expansions, plus local and overseas acquisitions.
Invida has acquired a stake in Indonesia-based MUGI, giving it the local manufacturing presence needed to offer partners access to “a vast untapped market”.
Rumours have resurfaced that Indian generics firm Piramal Healthcare is in talks with Sanofi-Aventis and Pfizer about a potential takeover.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
Millipore says that rebounding Big Pharma spending and biotechnology drove first-quarter 2010 gains.
DSM Biologics says combining its XD platform with newly-acquired Rhobust chromatography platform will create high yield, low cost bio-manufacturing option.
US drug packaging firm Comar says acquisition of Universal Container Corp (Unicon) provides capacity for growth, particularly in key liquid medication delivery device market.
AMPAC Fine Chemicals boosts reactor capacity 30 per cent with new manufacturing plant and says North America is attractive for API production.
US drugmaker Javelin Pharmaceuticals says Hospira’s takeover bid is “superior” and terminates agreement with Myriad Pharmaceuticals (MPI).
Silence Therapeutics says extension of RNAi drug delivery collaboration by Dainippon Sumitomo is evidence of technology’s potential.